查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2024755

脂質體阿黴素市場分析：按產品、應用和地區分類（2026-2034 年）

Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2025年全球脂質體阿黴素市場規模達14億美元。 IMARC Group預測，到2034年，該市場規模將達到21億美元，2026年至2034年的複合年成長率為4.53%。

脂質體阿黴素是一種化療藥物，用於治療多種自體免疫疾病以及肝癌、乳癌、子宮內膜癌、胃癌和腎癌。其作用機轉是抑製或減緩體內癌細胞的增生。這種藥物被包裹在一種稱為聚乙二醇化脂質體的脂質膜中，並透過靜脈注射注射給藥。阿黴素抑制癌細胞分裂和增殖所需的酶，而脂質體則有助於藥物在血液中停留更長時間，從而到達癌細胞並增強其療效。劑量根據患者的體重、身高和整體狀況而定。與傳統藥物相比，脂質體阿黴素的副作用較少，例如毒性、骨髓抑制、脫髮和噁心。

脂質體阿黴素市場趨勢：

在全球範圍內，骨癌、多發性骨髓瘤、卵巢癌和與後天免疫力缺乏缺乏症候群（AIDS）相關的卡波西氏肉瘤等慢性疾病的盛行率不斷上升，是推動市場成長的主要因素之一。這主要是由於大多數工作人群普遍存在久坐不動的生活方式和繁忙的工作安排，導致這些疾病的發病率顯著增加，從而對脂質體阿黴素製劑的需求產生了積極影響。此外，大眾對癌症治療方法的認知度不斷提高，也促進了市場成長。突破性奈米藥物的研發和化療藥物的改進等諸多進展也在推動市場成長。這些創新使得藥物能夠被輸送到體內特定部位並實現可控釋放。此外，醫療基礎設施的顯著改善，尤其是在開發中國家，以及腫瘤學領域廣泛的研發活動，預計也將推動市場成長。

本報告解答的主要問題

  • 全球脂質體阿黴素市場迄今的發展軌跡如何？預計未來幾年將如何發展？
  • 新冠疫情對全球脂質體阿黴素市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 從產品角度來看，市場是如何區隔的？
  • 按應用領域分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球脂質體阿黴素市場的結構是怎麼樣的？主要參與者有哪些？
  • 這個行業的競爭有多激烈？

目錄

第1章：序言

第2章：分析的範圍與方法

  • 分析目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 分析方法

第3章執行摘要

第4章：引言

第5章：全球脂質體阿黴素市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品

  • Doxil/Caelyx
  • Lipodox
  • Myocet
  • 其他

第7章 市場區隔：依應用

  • 白血病
  • 骨癌
  • 乳癌
  • 子宮內膜癌
  • 腎癌
  • 多發性骨髓瘤
  • 卡波西氏肉瘤
  • 其他

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Baxter International Inc.
    • Cipla Inc.
    • Johnson & Johnson
    • Merck KGaA
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceutical Industries Ltd
    • TTY Biopharm Company Limited
    • Zydus Cadila
Product Code: SR112026A3921

The global liposomal doxorubicin market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.53% during 2026-2034.

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

LIPOSOMAL DOXORUBICIN MARKET TRENDS:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

KEY MARKET SEGMENTATION:

Breakup by Product:

  • Doxil/Caelyx
  • Lipodox
  • Myocet
  • Others

Breakup by Application:

  • Leukemia
  • Bone Sarcoma
  • Breast Cancer
  • Endometrial Cancer
  • Kidney Cancer
  • Multiple Myeloma
  • Kaposi Sarcoma
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global liposomal doxorubicin market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global liposomal doxorubicin market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Liposomal Doxorubicin Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Doxil/Caelyx
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lipodox
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Myocet
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Leukemia
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Bone Sarcoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Breast Cancer
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Endometrial Cancer
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Kidney Cancer
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Multiple Myeloma
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Kaposi Sarcoma
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast
  • 7.8 Others
    • 7.8.1 Market Trends
    • 7.8.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Baxter International Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Cipla Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Johnson & Johnson
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Merck KGaA
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Pfizer Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Sun Pharmaceutical Industries Ltd
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Teva Pharmaceutical Industries Ltd
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 TTY Biopharm Company Limited
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Zydus Cadila
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio

List of Figures

  • Figure 1: Global: Liposomal Doxorubicin Market: Major Drivers and Challenges
  • Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2025
  • Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2025
  • Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2025
  • Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
  • Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
  • Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Liposomal Doxorubicin Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Liposomal Doxorubicin Market Forecast: Breakup by Product (in Million USD), 2026-2034
  • Table 3: Global: Liposomal Doxorubicin Market Forecast: Breakup by Application (in Million USD), 2026-2034
  • Table 4: Global: Liposomal Doxorubicin Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Liposomal Doxorubicin Market: Competitive Structure
  • Table 6: Global: Liposomal Doxorubicin Market: Key Players